Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.44 |
| ▸ | NCF1 | P14598 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28900531 | 0.82 | MEN1 (0.58) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL28628097 | 0.80 | MEN1 (0.56) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL887723 | 0.80 | MAPT (0.56) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL7697138 | 0.80 | KMT2A (0.56) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL31531064 | 0.80 | MEN1 (0.56) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL1775180 | 0.79 | MAPT (0.51) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL5735971 | 0.77 | MEN1 (0.61) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL9663555 | 0.77 | MAPT (0.61) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL1010648 | 0.77 | MEN1 (0.53) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 | |
| SCHEMBL30060467 | 0.77 | MEN1 (0.61) | MEN1MAPTKMT2ACYSLTR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833824-B1 | 3-CYCLOALKYLCARBONYL INDOLES AS CANNABINOID RECEPTOR LIGANDS | ABBVIE INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8383668-B2 | 11-beta-hydroxysteroid dehydrogenase type 1 active compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383683-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-8211925-B2 | Benzamide glucokinase activators | TRANSTECH PHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-8153798-B2 | Indole- and benzimidazole amides as hydroxysteroid dehydrogenase inhibitors | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-04-10 | — | — | US | disclosed |
| US-8138342-B2 | 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds | High Point Pharmacueticals, LLC (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HIGH POINT PHARMACEUTICALS, LLC (US) | 2012-01-05 | — | — | US | disclosed |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| WO-2004089380-A2 | PHARMACEUTICAL USE OF FUSED 1,2,4-TRIAZOLES | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089416-A2 | COMBINATION OF AN 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND AN ANTIHYPERTENSIVE AGENT | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089470-A2 | NEW AMIDE DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089471-A2 | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004089896-A1 | 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS | NOVO NORDISK A/S (DK) | 2004-10-21 | — | — | WO | disclosed |
| US-6759533-B2 | NOVEL INTERMEDIATES FOR THE SYNTHESIS OF CERTAIN NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-07-06 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| WO-2004002989-A1 | PROCESS AND INTERMEDIATES FOR MAKING NON-NUCLEOSIDE HIV-1 REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040002489-A1 | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2004-01-01 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | MEN1 3419/4885MAPT 3970/4885KMT2A 2570/4885 |
| US-20120004209-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD3B1, HSD11B2 | MEN1 1273/4885MAPT 3783/4885KMT2A 3823/4885 |
| US-20120010194-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Active Compounds | HSD11B1, HSD11B2, HSD3B1 | MEN1 1805/4885MAPT 3899/4885KMT2A 3370/4885 |
| US-20040002489-A1 | Process and intermediates for making non-nucleoside HIV-1 reverse transcriptase inhibitors | REV1, POLR2E, POLR2H | MEN1 3062/4885MAPT 4017/4885KMT2A 2558/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | MEN1 2380/4885MAPT 3897/4885KMT2A 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.